The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

A nephrologist argues that advancing kidney care in the US requires tailored guidelines addressing ethnic diversity & ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

chronic kidney disease and those who are overweight or obese. It is also approved for similar trials in the U.S. The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global force changing the future ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Eli Lilly & Co. has disclosed new calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1 (PDE1) inhibitors reported to be useful for the treatment of chronic kidney disease, ...